Nova Patents
WO2010143074A3

Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor

Abstract

The invention relates to a pharmaceutical dosage form which comprises a solid dispersion product comprising N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-l-cyclohex-l-en- 1-yl)methyl)piperazin- 1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1- ((phenylsulfanyl)methyl) propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or a salt, hydrate or solvate thereof, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer. The invention is further directed to processes for preparing the pharmaceutical dosage form and to use of the dosage form for treating proliferative disorders.

Term

No projected expiry on record.

  1. Priority and filed
  2. Published
  3. Today

Every citation, both ways

Citations
DocumentRelationOfficeCategoryCited duringRelevant claims
US2007027135A1CitesUnited States of AmericaADInternational search1-24
WO2009073835A1CitesWorld Intellectual Property Organization (WIPO)APInternational search1-24
RU2159107C2CitesRussian FederationYSupplementary search–
RU2318518C2CitesRussian FederationYSupplementary search–
CHEOL-MIN PARK ET AL: "Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 21, 13 November 2008 (2008-11-13), AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, pages 6902 - 6915, XP002574160, ISSN: 0022-2623, [retrieved on 20081008], DOI: 10.1021/JM800669SNon-patent––International search–
TSE CHRISTIN ET AL: "ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor", CANCER RESEARCH, vol. 68, no. 9, May 2008 (2008-05-01), pages 3421 - 3428, XP002601345, ISSN: 0008-5472Non-patent––International search–
TSE C. ET AL: "ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor", CANCER RESEARCH, vol. 68, no. 9, 2008, pages 3421 - 3428, XP002621449Non-patent––Supplementary search–